Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Median's eyonis LCS is software is reimbursable under Medicare at a rate between $601 to $700.

The FDA has cleared RevealDx’s AI-powered lung nodule risk assessment software, RevealAI-Lung, according to a company press ...

SAN ANTONIO, February 09, 2026--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board ...

RevealDX’s software analyses CT scans and assigns lung nodules with a Malignancy Similarity Index score to aid in lung cancer ...

Lung cancer rates overall have been declining in the U.S., but there is one group seeing an increase in lung cancer: People who never smoked.

The US Food and Drug Administration (FDA) has granted marketing clearance to Eyonis LCS, an artificial intelligence-powered ...

Visakhapatnam: Aninternational conference on Advanced Pulmonary Nodule Management was hosted here on Sunday. Organised by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A greater proportion of men vs. women nonsmokers had a ...

A Chinese research team has developed the world's first blood-based diagnostic kit that can tell whether lung nodules are benign or cancerous, including very small nodules that are often difficult to ...

If you meet the criteria for lung cancer screening — meaning you are or have a history of being a heavy smoker, and are between 50 and 80 years old — experts recommend an annual low-dose computerized ...

An artificial intelligence (AI)-powered tool that characterizes lung nodules has earned clearance from the FDA, according to ...